ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Sold by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC trimmed its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 43.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 212,246 shares of the company’s stock after selling 162,551 shares during the period. ClearPoint Neuro accounts for approximately 1.6% of Taylor Frigon Capital Management LLC’s holdings, making the stock its 17th largest holding. Taylor Frigon Capital Management LLC owned approximately 0.77% of ClearPoint Neuro worth $3,264,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CLPT. Oppenheimer & Co. Inc. acquired a new stake in ClearPoint Neuro in the 3rd quarter worth about $156,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in ClearPoint Neuro in the 3rd quarter worth about $366,000. Pekin Hardy Strauss Inc. acquired a new stake in ClearPoint Neuro in the 3rd quarter worth about $541,000. Verition Fund Management LLC acquired a new stake in ClearPoint Neuro in the 3rd quarter worth about $123,000. Finally, XTX Topco Ltd boosted its stake in ClearPoint Neuro by 53.0% in the 3rd quarter. XTX Topco Ltd now owns 19,900 shares of the company’s stock worth $223,000 after buying an additional 6,890 shares during the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Lake Street Capital lifted their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st. B. Riley lifted their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Price Performance

NASDAQ CLPT opened at $17.22 on Thursday. The firm has a market capitalization of $475.01 million, a P/E ratio of -24.96 and a beta of 1.03. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $19.22. The business’s 50-day simple moving average is $16.67 and its 200-day simple moving average is $13.80.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The company had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. On average, equities research analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.